33 completed. 33 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 33 | Completed 33 |
| Phase 2 | 12 | Completed 12 |
Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Tafasitamab, Tafasitamab plus lenalidomide - Diffuse Large B-cell Lymphoma | Phase 1 | Completed | MorphoSys AG | 66 | 2019-12-11 | 2024-10-16 |
| Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies Venetoclax, Selinexor - Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Completed | Sanjay Mohan | 78 | 2019-06-21 | 2026-10-29 |
| Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Abexinostat, Ibrutinib - Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 15 | 2019-05-29 | 2025-04-25 |
| Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 188 | 2019-05-23 | 2025-08-21 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Zilovertamab vedotin - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 91 | 2019-03-14 | 2024-01-12 |
| Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 1 | Completed | Northwestern University | 12 | 2019-03-13 | 2025-06-18 |
| Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Tisagenlecleucel, Pembrolizumab - Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Novartis Pharmaceuticals | 12 | 2018-10-09 | 2022-08-15 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies INCAGN02385 - Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer | Phase 1 | Completed | Incyte Biosciences International Sàrl | 22 | 2018-06-18 | 2020-10-30 |
| A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 RO6870810, Venetoclax, Rituximab - Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma | Phase 1 | Completed | Hoffmann-La Roche | 39 | 2017-08-28 | 2022-01-24 |
| A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies MEDI7247 - Acute Myeloid Leukemia, Multiple Myeloma | Phase 1 | Completed | MedImmune LLC | 67 | 2017-03-29 | 2020-02-28 |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas Venetoclax, Rituximab, Etoposide - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 | Completed | Weill Medical College of Cornell University | 31 | 2017-02-06 | 2022-08-24 |
| MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) MEDI4736, tremelimumab, AZD9150 - Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | MedImmune LLC | 32 | 2016-07-13 | 2019-02-27 |
| Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation Leukapheresis, Cyclophosphamide, Fludarabine - Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | University College, London | 10 | 2016-06-01 | 2023-04-28 |
| KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma KPT-330, Rituximab, Etoposide - Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Weill Medical College of Cornell University | 22 | 2015-12-11 | 2022-04-12 |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Ibrutinib, MEDI4736 - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 61 | 2015-05-01 | 2019-06-27 |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Carfilzomib, Belinostat - Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2014-10-01 | 2018-01-25 |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) Pembrolizumab, Lenalidomide 20 mg, Lenalidomide 25 mg - Myelodysplastic Syndrome, Multiple Myeloma | Phase 1 | Completed | Merck Sharp & Dohme LLC | 197 | 2013-11-22 | 2021-08-04 |
| Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma Gemcitabine, Dexamethasone, Cisplatin - Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Canadian Cancer Trials Group | 21 | 2013-10-01 | 2026-03-27 |
| Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia Clofarabine, Mitoxantrone - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | New York Medical College | 41 | 2013-03-01 | 2022-10-25 |
| A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) OTX015/Birabresib - Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 141 | 2012-12-14 | 2021-01-26 |
Showing 20 of 33. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (33) · Lymphoma, Mantle-Cell (8) · Lymphoma, Follicular (7) · Lymphoma, Non-Hodgkin (7) · Leukemia, Myeloid, Acute (6) · Multiple Myeloma (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Waldenstrom Macroglobulinemia (4) · Burkitt Lymphoma (3) · Lymphoma, T-Cell, Peripheral (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2)
Hemic and Lymphatic Diseases (33) · Immune System Diseases (33) · Immunoproliferative Disorders (33) · Lymphatic Diseases (33) · Lymphoma, B-Cell (33) · Lymphoproliferative Disorders (33) · Neoplasms (33) · Neoplasms by Histologic Type (33) · Lymphoma (29) · Lymphoma, Non-Hodgkin (26) · Hematologic Diseases (11) · Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8)
Rituximab (11) · Cyclophosphamide (5) · Vincristine (5) · Doxorubicin (3) · Etoposide (3) · Lenalidomide (3) · Prednisone (3) · venetoclax (3) · Carboplatin (2) · Clofarabine (2) · Dexamethasone (2) · Gemcitabine (2) · MLN 8237 (2) · durvalumab (2) · ibrutinib (2)
Hoffmann-La Roche (2) · Massachusetts General Hospital (2) · MedImmune LLC (2) · Millennium Pharmaceuticals, Inc. (2) · Weill Medical College of Cornell University (2) · Acrotech Biopharma Inc. (1) · Canadian Cancer Trials Group (1) · Celgene (1) · Fred Hutchinson Cancer Center (1) · Genentech, Inc. (1) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (1) · Incyte Biosciences International Sàrl (1) · Lund University Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1)
United States (24) · France (6) · Spain (6) · United Kingdom (5) · Canada (3) · Italy (3) · Austria (2) · Belgium (2) · Germany (2) · South Korea (2) · Australia (1) · Czechia (1) · Denmark (1) · Ireland (1) · Israel (1)
Jeremy Abramson, MD (2) · Alejandro Martin (1) · Anthony J Reiman (1) · Brenda Sandmaier (1) · Dolores Caballero (1) · Emily Liu (1) · Farrokh Dehdashti, M.D. (1) · Gareth Morgan, Prof. (1) · Gilles Salles, MD (1) · Jeremy S. Abramson, M.D. (1)
PMID 34515338, PMID 24352795, PMID 26341814, PMID 27063977, PMID 27063978, PMID 27354476, PMID 28490569, PMID 29903707, PMID 30082475, PMID 30301414, PMID 30935953, PMID 30937889, PMID 31395089, PMID 31609651, PMID 32556281, PMID 32705923, PMID 32770353, PMID 32871584, PMID 34398557, PMID 34581757, PMID 34634256, PMID 35244520, PMID 36044388, PMID 36398795, PMID 37369099, PMID 37485564, PMID 38319241, PMID 38683495, PMID 39319495, PMID 40641817, PMID 40802906, PMID 41796974, PMID 42832423
2015 (1), 2017 (1), 2018 (1), P01CA078902 (1), P30CA015704 (1), P30CA060553 (1)